Pfizer (PFE) BioNTech (BNTX) will stop US COVID-19 vaccine study in healthy adults ages 50 to 64 due to slow enrollment

The decision for Pfizer and BioNTech to halt their COVID-19 vaccine study in the specified age group reflects challenges in enrollment, which may signal concerns over vaccine uptake or market saturation.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Atlanta Fed GDPnow (Q1): 1.9% (prev. 2.0%)

NATO worries US Preisdent Trump will defang alliance as US threatens exit

Pfizer (PFE) BioNTech (BNTX) will stop US COVID-19 vaccine study in healthy adults ages 50 to 64 due to slow enrollment

US sells 17-wk bills at high-rate 3.615%, B/C 2.95x

US military officials are planning for two potential ground assaults in Iran: one on Kharg Island, the hub of the country’s energy industry, and the other to seize enriched uranium, Atlantic reports, citing source

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This development could impact investor sentiment regarding their vaccine-related revenue projections, and may also affect broader market confidence in vaccine advancements and public health strategies.

Related headlines

The whole workspace, free to try.

Try it free